Cellular Biomedicine Acquires CAR-T Technology from China Hospital
publication date: Feb 9, 2015
Cellular Biomedicine Group, a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing. The two groups will form a partnership for further development of the products in China. The PLA Hospital has already conducted early clinical trials of the technology on CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer. The data from the Phase I and II trials is included in the deal. More details....
Stock Symbol: (NSDQ: CBMG)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.